316 related articles for article (PubMed ID: 28523942)
21. Powering up the molecular therapy of RNA interference by novel nanoparticles.
Liao W; Li W; Zhang T; Kirberger M; Liu J; Wang P; Chen W; Wang Y
Biomater Sci; 2016 Jun; 4(7):1051-61. PubMed ID: 27221980
[TBL] [Abstract][Full Text] [Related]
22. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
[TBL] [Abstract][Full Text] [Related]
23. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
[TBL] [Abstract][Full Text] [Related]
24. Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential.
Larsson M; Huang WT; Liu DM; Losic D
Cancer Treat Rev; 2017 Apr; 55():128-135. PubMed ID: 28363142
[TBL] [Abstract][Full Text] [Related]
25. Advances in siRNA delivery strategies for the treatment of MDR cancer.
Subhan MA; Attia SA; Torchilin VP
Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
[TBL] [Abstract][Full Text] [Related]
26. The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.
Youngren-Ortiz SR; Chougule MB
Hawaii J Med Public Health; 2017 Nov; 76(11):318-325. PubMed ID: 29164017
[TBL] [Abstract][Full Text] [Related]
27. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
Xu WW; Liu DY; Cao YC; Wang XY
Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
[TBL] [Abstract][Full Text] [Related]
28. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
29. Nanoparticles containing insoluble drug for cancer therapy.
Guo S; Huang L
Biotechnol Adv; 2014; 32(4):778-88. PubMed ID: 24113214
[TBL] [Abstract][Full Text] [Related]
30. SiRNA delivery: challenges and role of carrier systems.
Shegokar R; Al Shaal L; Mishra PR
Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
[TBL] [Abstract][Full Text] [Related]
31. Targeted Liposomes for siRNA Delivery to Cancer.
Eloy JO; Petrilli R; Raspantini GL; Lee RJ
Curr Pharm Des; 2018; 24(23):2664-2672. PubMed ID: 30084323
[TBL] [Abstract][Full Text] [Related]
32. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in Treatment of Lung Cancer: Nanoparticle-based Drug and siRNA Delivery Systems.
Gencer A; Duraloglu C; Ozbay S; Ciftci TT; Yabanoglu-Ciftci S; Arica B
Curr Drug Deliv; 2021; 18(2):103-120. PubMed ID: 32748745
[TBL] [Abstract][Full Text] [Related]
34. Nanotechnology lights up the antitumor potency by combining chemotherapy with siRNA.
Sun J; Ogunnaike EA; Jiang X; Chen Z
J Mater Chem B; 2021 Sep; 9(36):7302-7317. PubMed ID: 34382987
[TBL] [Abstract][Full Text] [Related]
35. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
36. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
37. [Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].
Chen WG; Wang SB
Yao Xue Xue Bao; 2013 Jul; 48(7):1091-8. PubMed ID: 24133974
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanoparticles for short interfering RNA delivery.
Leung AK; Tam YY; Cullis PR
Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
[TBL] [Abstract][Full Text] [Related]
39. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
[TBL] [Abstract][Full Text] [Related]
40. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L
Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
